Fig. 9
EO-altered breast cancer cell proliferation can be modulated by the cytokines NOV and decorin. MDA-MB-231, MDA-MB-231BRMS, or MCF-7 cells were plated at 1 × 105 cells/cm2 in 35 × 10 mm dishes, then treated with either MC3T3-E1 CM, corresponding EO variant CM (e.g., MDA-MB-231 cells treated with EO-231 CM) or corresponding EO variant CM in the presence of either anti-NOV or decorin protein. Three individual replicates per time point per condition were plated. On days 1, 2, 3, 4, and 5, cancer cells were detached and counted using a hemocytometer. a MDA-MB-231 cells treated with either MC3T3-E1, EO-231 CM, or EO-231 CM plus anti-NOV. b MDA-MB-231BRMS cells treated with either MC3T3-E1, EO-BRMS CM, or EO-BRMS CM plus anti-NOV. c MCF-7 cells treated with either MC3T3-E1, EO-MCF7 CM, or EO-MCF7 CM plus anti-NOV. d MDA-MB-231 cells treated with either MC3T3-E1, EO-231 CM, or EO-231 CM plus decorin protein. e MDA-MB-231BRMS cells treated with either MC3T3-E1, EO-231 CM, or EO-231 CM plus decorin protein. f MCF-7 cells treated with either MC3T3-E1, EO-MCF7 CM, or EO-MCF7 CM plus decorin protein. #P < 0.05, **P < 0.005 EO CM treatment vs. anti-NOV or decorin treatment. N = 3 per condition, per time point